Two items of recent pandemic news: Billions to develop antivirals that can be taken by mouth; and a hard fail in a vaccine Phase III trial. Plus news briefs and a frippery. CureVac falls flat You may have heard by … Continue reading →
Three items of recent pandemic news: the seriousness of the Delta variant; how a bitter taste might predict the severity of a Covid-19 outcome; and results from the Novavax Phase III trial. Plus news briefs and a frippery. Novavax results … Continue reading →
Two items of recent pandemic news: Studies point to long-lasting, possibly lifelong immunity from natural infection; and rapid developments in the highly political question of where SARS-CoV-2 came from. Plus news briefs and a pair of fripperies. Origin, again It … Continue reading →
Herewith three items of pandemic news you may have missed: Vitamin D levels vs. infection probability in Black people; variant viruses infecting animals; and the roller coaster that is AstraZeneca’s Phase III results announcement. Plus news briefs and a frippery. … Continue reading →
Herewith three items of pandemic news you may have missed recently: Cautionary lessons from Brazil’s second wave in Manaus; CureVac’s manufacturing partnership with Bayer; and long Covid’s entanglement with autoantibodies. Plus news briefs and a frippery. Autoantibodies and long Covid … Continue reading →
Herewith three items of pandemic news you may have missed recently: The South African variant shows up in the US; pharma giants are helping each other out; and Novavax reads out preliminary results. Plus news briefs and a frippery. Novavax … Continue reading →
Preliminary results are out for the J&J single-shot vaccine candidate. Efficacy against moderate and severe Covid-19 after 28 days was 72% in the US and 66% overall worldwide, and did not vary by age or race. Efficacy against severe disease … Continue reading →
Herewith three items of pandemic news you may have missed recently: More on virus variants; Novavax’s Phase III study is leaking volunteers; and vaccine hesitancy in the Black population. Plus news briefs and a frippery. Black vaccine hesitancy For all … Continue reading →
Herewith three items of pandemic news you may have missed recently: Infected gorillas; inhalable therapies and prophylactics; and the greater difficulty of testing new vaccine candidates once some have been authorized. Plus the accustomed frippery. After authorized vaccines, testing later … Continue reading →
Herewith three items of pandemic news you may have missed recently: psychotic sequelae to Covid-19; Novavax’s Phase III begins in the US; and as we move into year 2, what we may choose to forget. Plus the usual frippery. What … Continue reading →
The FDA’s outside committee of experts, the VRBPAC, is meeting again today, one week after they voted to authorize the Pfizer / BioNTech vaccine. Pretty much everyone expects that the committee will give the nod to Moderna’s candidate this afternoon. … Continue reading →
Herewith three items of pandemic news you may have missed recently: How wearable computers could predict Covid-19; the complicated situation with autoantibodies; and the late-stage trial of German company CureVac’s vaccine candidate. Plus the accustomed frippery. CureVac’s candidate enters Phase … Continue reading →
As expected, on Thursday the FDA’s panel of outside advisors recommended that Pfizer / BioNTech’s vaccine candidate, BNT162b2, be granted an emergency use authorization. The vote was 17 to 4 with one abstention. The committee that met (all day) yesterday … Continue reading →
Herewith three items of pandemic news you may have missed recently: More on mixing & matching vaccines; putting a lid on Johnson & Johnson’s US Phase III; and a deeper dive into Oxford / AstraZeneca’s data. Plus a frippery. A … Continue reading →
Here are three more items of pandemic news you may have missed recently: US vaccine willingness is on the rise; it’s OK for infected mothers and newborns to cohabit; and the first virus authorization is imminent. Plus a frippery. First … Continue reading →
